Treatment of canine osseous tumors with photodynamic therapy: a pilot study.

Photodynamic therapy uses nonthermal coherent light delivered via fiber optic cable to locally activate a photosensitive chemotherapeutic agent that ablates tumor tissue. Owing to the limitations of light penetration, it is unknown whether photodynamic therapy can treat large osseous tumors. We determined whether photodynamic therapy can induce necrosis in large osseous tumors, and if so, to quantify the volume of treated tissue. In a pilot study we treated seven dogs with spontaneous osteosarcomas of the distal radius. Tumors were imaged with MRI before and 48 hours after treatment, and the volumes of hypointense regions were compared. The treated limbs were amputated immediately after imaging at 48 hours and sectioned corresponding to the MR axial images. We identified tumor necrosis histologically; the regions of necrosis corresponded anatomically to hypointense tissue on MRI. The mean volume of necrotic tissue seen on MRI after photodynamic therapy was 21,305 mm(3) compared with a pretreatment volume of 6108 mm(3). These pilot data suggest photodynamic therapy penetrates relatively large canine osseous tumors and may be a useful adjunct for treatment of bone tumors.

Canine spinal meningiomas and nerve sheath tumours in 34 dogs (2008-2016): Distribution and long-term outcome based upon histopathology and treatment modality.

The purpose of this retrospective, multicentre case series was to describe the outcome following surgery and/or radiation of spinal meningiomas and nerve sheath tumours (NSTs) based upon treatment modality, with a specific aim to evaluate the survival times and time to recurrence following treatment for each histopathological diagnosis. Our hypothesis was that the addition of radiation therapy modalities to treatment will yield longer time to recurrence of clinical signs and survival time. Thirty-four dogs met the inclusion criteria of histopathologically diagnosed extramedullary spinal meningioma or NST. Sixteen extramedullary spinal meningiomas and 18 NSTs were diagnosed. A diagnosis of meningioma was associated with a significantly longer survival time compared with NSTs, with median survival times (MST) of 508 days (95% confidence interval [CI]: 66-881) vs 187 days (95% CI: 76-433; P = .02). Dogs (seven) treated with stereotactic radiation therapy (SRT) for recurrence after surgery alone or SRT alone as their initial treatment gained an additional 125 to 346 days survival time.

Applying genomics-related technologies for Africa's health needs.

While the past century has seen significant improvement in life expectancies in the developed world, it has also witnessed diseases like HIV/AIDS, malaria and tuberculosis ravage populations in the developing world. In some Sub-Saharan African countries, life expectancies have plummeted to less than 40 years--nearly half of those in developed countries. Unequal access to the benefits of science and technology, including medical advances, exacerbate this disparity. In order to address the challenge of global health inequities and strengthen the role of science and technology innovation in contributing to real solutions, the Canadian Program on Genomics and Global health (CPGGH), based at the University of Toronto, has identified three guiding questions: Which genomics-related technologies are most likely to improve the health of people in developing countries?; How can developing countries harness these technologies for health development?; and What can industrialized countries do to assist developing countries?

Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder.

Canine transitional cell carcinoma (TCC) of the bladder has historically been treated with a combination of chemotherapy, cyclooxygenase inhibitors and radiation therapy. While surgery has been used to treat TCC of the bladder, its efficacy has yet to be established. Thirty-seven client owned dogs that underwent partial cystectomy +/- various nonsurgical treatments for TCC were retrospectively evaluated. The overall median progression-free interval (PFI) was 235 days and the median survival time (ST) was 348 days. Prognostic factors identified on univariate analysis significant for ST were age, tumor location, full thickness excision and frequency of piroxicam administration. Prognostic factors significant for PFI were full thickness excision and frequency of piroxicam administration. The median ST with partial cystectomy and daily piroxicam therapy, with or without chemotherapy, was 772 days. Dogs with non-trigonal bladder TCC treated with full thickness partial cystectomy and daily piroxicam (+/- chemotherapy) may have improved outcome compared to dogs treated with medical therapy.

Effect of stage of diestrus and number of cloprostenol (ICI 80, 996) injections on intervals to estrus, LH peak and ovulation in heifers.

Intervals to the onset of estrus, luteinizing hormone (LH) peak and ovulation were compared in diestrous heifers after each of two cloprostenol treatments. Diestrous heifers were grouped at the first treatment (T1) according to day of the cycle, with heifers on days 5 through 8 designated as early diestrus and heifers on days 9 through 17 designated as late diestrus. Cloprostenol treatment was repeated (T2) 11 days after T1, at which time heifers in both groups were at similar stages of the estrous cycle. Visual observation, identification of the preovulatory LH peak, and rectal palpation were utilized to estimate data parameters. Split-plot analysis of variance showed a significant treatment x group interaction (P < .05). Time from prostaglandin treatment to the onset of estrus was similar for the early diestrous group after T1 (x = 53.1 hours ) and the early and late diestrous groups after T2 (x = 49.4 hours and 45.4 hours respectively). This interval was longer (P < .05) for the late diestrous group after T1 (x = 60.8 hours ) than for either group after T2, but not different from that for the early diestrous group after T1. Serum progesterone concentrations were higher (P < .05) at the time of T1 in the late diestrous group (x = 5.8 ng/ml ) than in the early diestrous group (x = 3.0 ng/ml ) or in either group at the time of T2 (x = 2.8 and 3.2 ng/ml respectively). Over all heifers, the synchrony of the onset of estrus was more precise (P < .05) after T2 than T1. Intervals from the onset of estrus to ovulation were not affected by group or treatment (overall mean = 24.4 +/- 1.0 hours, n = 42). We conclude that different recommendations for appointment artificial insemination (AI) may be indicated depending on the number of prostaglandin injections which are used in a prostaglandin synchronization program prior to insemination.

Corpus luteum function and pregnancy rate in lactating dairy cows given human chorionic gonadotropin at middiestrus.

The effect of human chorionic gonadotropin (HCG) on corpus luteum (CL) function in lactating dairy cows and its subsequent effect on pregnancy rates achieved with artificial insemination was studied in two parts. In Part 1, four IM injections at intervals of seven days or two IM injections at a 14 day interval of HCG (10,000 IU) were given to two groups of six cows each, groups A and B respectively, beginning on days 9, 10 or 11 of the estrous cycle. Ten control cows were given 10 ml of isotonic saline solution on days 9, 10 or 11. Interestrous intervals were prolonged by an average of 8.1 and 3.4 days for groups A and B respectively over controls. In Part 2, 200 lactating dairy cows on nine farms were assigned, on an alternate basis at insemination, to control or treatment groups to study the effect of CL prolongation via HCG on pregnancy rate. A single injection of HCG (10,000 IU) was given 10, 11 or 12 days after a first or second insemination. Pregnancy rates for control and treated cows were similar (64 101 = 63% and 58 99 = 59% respectively). Interestrous intervals of treated nonpregnant cows were prolonged by approximately five days. Providing additional time for developing embryos to become established in utero by delaying luteolysis did not improve pregnancy rates achieved with artificial insemination in lactating dairy cows.

Retained fetal membranes in cows: Manual removal versus nonremoval and its effect on reproductive performance.

Sixteen primiparous Holstein cows with retained fetal membranes (RFM) were studied for postpartum prostaglandin release, uterine infection and resumption of estrous cyclicity after manual removal of RFM (eight cows) versus leaving the RFM untreated (eight cows). The RFM were results of induced parturition on Day 274 of gestation. Seventeen non-RFM primiparous cows were controls. The 15-keto-13, 14-dihydro-metabolite of prostaglandin F(2alpha) (PGFM) was measured in daily blood samples. Aerobic and anaerobic bacteria were cultured from weekly uterine swabs from Week 3 until results were negative. Resumption of estrous cyclicity was determined by milk progesterone three times weekly. Manual removal caused an immediate and large but short-lived increase in PGFM, probably due to the physical damage of uterine tissue. No sustained difference in postpartum PGFM release between cows with RFM manually removed and cows with RFM left untreated was detected. Non-RFM controls had lowest PGFM concentrations. Uterine infections were more frequent and more severe after manual removal of RFM. Untreated RFM-cows and controls were similarly affected. Most infections involved Actinomyces (formerly Corynebacterium ) pyogenes and/or Fusobacterium necrophorum . Actinomyces pyogenes was isolated in the third week postpartum in 5 8 cows with RFM manually removed versus 2 8 cows with RFM left intact and in 2 17 controls. Manual removal prolonged the interval from calving to first functional corpus luteum by 20 d. This study, using RFM resulting from induced parturition, shows that manual removal of RFM can delay the postpartum return to normal reproductive status without altering PGFM profiles.

Does intrauterine site of insemination in cattle really matter?

Two trials were conducted to determine the influence of semen placement on pregnancy rate in dairy heifers and cows. Seventy-two dairy heifers were artificially inseminated (AI) 10 to 12 h after the first detection of estrus. Control heifers (n = 25) were inseminated at the junction of the uterine body and internal cervical os. The remaining heifers were inseminated deep in one uterine horn, 3 to 5 cm anterior to the external bifurcation. Twenty-three heifers were inseminated in the horn ipsilateral to the ovary bearing the ovulatory follicle, and 24 heifers were inseminated in the contralateral horn. Pregnancy rates did not differ for the three groups of heifers. In a second trial, 64 inseminations were performed in 38 nonlactating, adult dairy cattle. Thirty-one inseminations were made deep in the uterine horn ipsilateral to the ovary bearing the ovulatory follicle and 33 in the contralateral horn. Pregnancy rates were similar for both groups. Combining both trials, pregnancy rates for ipsilateral and contralateral inseminations were equal (32 54 = 59% and 34 57 = 60% , respectively). Therefore, placement of semen in one horn of the uterus does not appear to be a cause of decreased or increased pregnancy rate with AI.

Simultaneous injection of PGF2alpha and GnRH into diestrous dairy cows delays return to estrus.

Simultaneous injections of prostaglandin F2alpha (PGF) and gonadotropin releasing hormone (GnRH) or saline were given to 32 diestrous dairy cows to test the ability of GnRH to improve estrous and ovulation synchrony beyond that of PGF alone. Cows were randomly assigned to receive PGF on Day 8 or Day 10 of the estrous cycle (estrus = Day 0), and all cows were further assigned to simultaneous injection of GnRH or saline. Corpus luteum (CL) regression, return to estrus and follicular activity were monitored by plasma progesterone assay, twice-daily estrous detection and ultrasonographic examination, respectively. Plasma progesterone concentrations declined to <1.0 ng/ml at 24 hours after PGF in all cows and were not affected by GnRH. Gonadotropin releasing hormone inducted premature ovulation or delayed return to estrus in 7 of 8 cows treated with PGF/GnRH on Day 8 and 3 of 8 cows treated with PGF/GnRH on Day 10. Further, cows with premature GnRH-induced ovulations failed to develop and maintain a fully functional CL, and all returned to estrus 7 to 13 days after the induced ovulation. These data indicate that GnRH administered simultaneously with a luteolytic dose of PGF disrupts follicular dynamics and induces premature ovulation or delays normal return to estrus and, therefore, does not improve the synchrony of estrus and ovulation achieved with PGF alone.

Simultaneous injection of follicle stimulating hormone (FSH) and the prostaglandin F2alpha analog cloprostenol (PGF) disrupts follicular activity in diestrous dairy cows.

Simultaneous injections of PGF and FSH or saline were given to 32 Holstein cows to test their combined ability to improve estrous and ovulation synchrony beyond that of PGF alone. All the cows were randomly assigned to receive PGF on either Day 8 or Day 10 of the estrous cycle (estrus = Day 0), and all the cows in each group were further assigned to simultaneous injection of either FSH or saline. Regression of the corpus luteum (CL), return to estrus and follicular activity were monitored by plasma progesterone assay, twice-daily estrous detection and ultrasonographic examination, respectively. Plasma progesterone concentrations declined to <1.0 ng/ml at 24 hours after PGF treatment in all the cows and FSH did not affect this decline. Return to estrus was not affected by FSH treatment in cows treated on Day 8 or Day 10; however, FSH disrupted normal follicular activity and either delayed normal ovulation following estrus or induced premature ovulation or cyst formation in 4 of 8 PGF/FSH (Day 8) cows and 5 of 8 PGF/FSH (Day 10) cows. These data indicate that exogenous FSH administered simultaneously with a luteolytic does of PGF does not maintain viability of large, dominant follicles and, therefore, is not an effective method for the synchronization of estrus and ovulation.

Single appointment insemination for heifers after prostaglandin or progestin synchronization of estrus.

Pregnancy rates to a single appointment insemination were compared in seven groups of beef or dairy heifers following estrus synchronization with the prostaglandin F(2a) product, cloprostenol, versus the progestín product, Syncro-Mate-B. For cloprostenol synchronization, two injections of cloprostenol were given 11 d apart, with insemination occurring at 61+/-1 h after the second injection. The Syncro-Mate-B treatment consisted of a norgestomet/estradiol injection and a norgestomet implant on Day 0, followed by insemination at 49+/-1 h after implant removal on Day 9. Treatments were coordinated so all heifers in each group were housed together at the time of and for 48 h before a common insemination time so that the treatment received by individual heifers was not known. Overall pregnancy rates did not differ between treatment groups: 42% for 111 heifers treated with cloprostenol and 38% for 108 heifers treated with Syncro-Mate-B. Four blood samples per heifer taken during each replicate showed that two groups (n = 67) had many noncyclic heifers, while five groups (n = 152) had very few. Differences in pregnancy rates between these categories existed for both estrus synchronization methods, 18 versus 53% for cloprostenol and 21 versus 45% for Syncro-Mate-B. Thus the two methods were equally effective for cyclic heifers and equally ineffective for noncyclic heifers.

Role of blood cells in degradation of progesterone in bovine blood.

The nature of progesterone decline in samples of bovine blood as affected by whole blood incubation time and temperature was investigated in 3 experiments. In 2 experiments, progesterone concentrations were determined in plasma, in hemolyzed (by freezing and thawing) blood, and in washed blood cells and blood cell washes before and after 8 hours of incubation at 22 C to study the effect of RBC on detected progesterone. In the third experiment, the effect of alteration in RBC metabolism on progesterone degradation by these cells was studied by using potassium oxalate-sodium fluoride as anticoagulant. Results of these experiments indicated that (a) progesterone was significantly reduced because of whole blood incubation time and temperature, (b) lost progesterone was not detectable on or in blood cells indicating chemical degradation of progesterone, (c) intact blood cells were needed to obtain the decrease in the progesterone, (d) a small amount of circulating blood progesterone was associated with blood cells, and (e) degradation of bovine blood progesterone by blood cells was dependent on the glycolytic process. Potassium oxalate-sodium fluoride anticoagulant and refrigeration provided the best progesterone results when blood samples were not processed immediately after collection.

Effect of gonadotropin-releasing hormone and human chorionic gonadotropin on cows with ovarian follicular cysts.

Ovarian follicular cysts of cattle were defined as follicular structures (larger than or equal to 2.5 cm, diameter) which persisted for 10 days or longer in the absence of functional luteal tissue. Thirty dairy cows with ovarian follicular cysts were allotted to 6 groups (5 cows per group) and each was given 0 (saline solution), 25, 50, 100, 150, or 250 mug of gonadotropin-releasing hormone (GnRH) by intramuscular (IM) injection. Samples of blood were collected before GnRH was injected (0 hour), at 0.25, 0.50, 0.75, 1, 2, 3, and 4 hours, and at 1, 7, 11, 15, and 20 days after treatment. Five additional cows with follicular cysts were treated IM with 10,000 units of human chorionic gonadotropin (HCG), and blood sample collections were made before treatment (0 hour) and on days 1, 7, 11, 15, and 20 after treatment. Serum luteinizing hormone (LH) concentration was not altered in cows given saline solution, but was increased significantly in cows given any of the doses of GnRH (in a dose-related manner). Peak LH responses occurred about 2 hours after GnRH was given, and by 4 hours LH was beginning to decrease. Serum progesterone concentrations increased by more than 2.0 ng/ml by day 11 after treatment in 18 of 20 cows treated with 50, 100, 150, or 250 mug of GnRH. Progesterone responses in these cows were greater (P less than 0.05) than in cows given saline solution or a 25-mug dose of GnRH. Mean progesterone response to the 4 large doses of GnRH was similar in magnitude and duration to serum progesterone changes during the leutal phase of the bovine estrous cycle. After cows were treated with HCG, serum progesterone values were similar to those in cows given GnRH (50 to 250 mug).

Decline in assayable progesterone in bovine plasma: effect of time, temperature, anticoagulant, and presence of blood cells.

Jugular vein blood samples collected from 5 Holstein-Friesian cows during the luteal phase of the estrous cycle were incubated at 4 C, 22 C, and 37 C for 0, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours. Blood samples were centrifugated after each incubation period, and plasma was frozen for later progesterone assay. Mean progesterone concentration in blood samples incubated at 4 C, 22 C, and 37 C decreased from 5.7 ng/ml at 0 hour to minimum concentrations of 3.5 ng/ml at 12 hours, 0.9 ng/ml at 12 hours, and 1.0 ng/ml at 8 hours, respectively. The first progesterone concentration which was significantly different from the initial value (0 hour) was at the 8-hour incubation period for blood samples incubated at 4 C and at the 1-hour incubation period for blood samples incubated at 22 C and 37 C. Progesterone concentration decreased similarly when blood samples were collected into heparinized tubes or EDTA tubes and incubated at 22 C for 0, 6, and 12 hours. Incubating harvested plasma or serum for 0 to 6 hours at 37 C had no effect on progesterone concentrations (7.9 and 8.2 ng/ml for plasma, and 6.9 and 6.6 ng/ml for serum.

Cytoplasmic estrogen and progesterone receptors in canine endometrium during the estrous cycle.

Estradiol and progesterone receptors (ER, PR) were characterized and measured in cytosols from canine endometrium, using saturation and sucrose-gradient centrifugation radioassays. Both receptors were demonstrated to be steroid- and tissue-specific saturable proteins, which bound the respective steroids with high affinity (dissociation constant [Kd] approximately 10(-9)M). Serum estradiol, progesterone, and endometrial cytosol receptor concentrations and receptor-binding affinity were measured for 25 bitches from which samples were obtained at 5 stages of the estrous cycle (5 bitches each): anestrus (A), the 3rd day of proestrus (P3), the 3rd day of estrus (E3), the 12th day after onset of estrus (E12), and the 28th day after onset of estrus (E28). Mean (+/- SEM) serum estradiol concentrations were 17.0 +/- 2.2 (A), 55.4 +/- 5.0 (P3), 89.4 +/- 24.9 (E3), 41.0 +/- 5.9 (E12), and 50.6 +/- 3.9 (E28) pg/ml. Mean (+/- SEM) serum progesterone concentrations were 0.4 +/- 0.1 (A), 1.5 +/- 0.2 (P3), 17.3 +/- 7.5 (E3), 41.6 +/- 9.5 (E12), and 25.8 +/- 3.2 (E28) ng/ml. Concentrations of ER increased significantly from 1.06 pmol/g of uterus during stage A to a peak concentration of 6.18 pmol/g of uterus at E12, followed by a gradual decrease to 0.69 pmol/g of uterus by E28. The PR concentrations increased from 3.01 pmol/g of uterus in stage A to 17.32 pmol/g of uterus at P3; PR concentrations, thereafter, decreased gradually to 1.85 pmol/g of uterus by E28. Dissociation constants were significantly higher at E12 for the ER (Kd = 2.6645 X 10(-9)M) and at P3 for the PR (Kd = 5.8282 X 10(-9)M) than at the other stages examined, indicating a decrease in receptor affinity during the periods of high receptor concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Plasma concentrations of luteinizing hormone and adrenocorticotropic hormone in blood collected during the luteal and follicular phases of the estrous cycle in cows.

Luteinizing hormone (LH) and ACTH concentrations were measured in plasma from 7 cows to determine whether ACTH secretion changes with the phase of the estrous cycle, and to determine whether any ACTH peaks are associated with LH peaks. Blood was collected every 5 minutes for 190 minutes during the luteal and follicular phases of the estrous cycle. Radioimmunoassays were used to measure ACTH and LH in plasma. Mean concentration of ACTH in all cows did not differ significantly between luteal (35.1 +/- 8.0 pg/ml) and follicular (37.5 +/- 9.4 pg/ml) phases of the estrous cycle. Mean concentration of luteal-phase LH of all cows (2.0 +/- 1.1 ng/ml) was significantly (P less than 0.01) lower than mean concentration of follicular-phase LH (5.4 +/- 1.6 ng/ml). Frequency of peaks in ACTH concentration was low during the sampling period. Mean number of luteal-phase ACTH peaks (0.29 +/- 0.49) was not significantly different from that of follicular-phase samples (0.43 +/- 0.530). Unlike ACTH, mean frequency of LH peaks was significantly (P less than 0.05) higher in plasma from cows in the follicular phase of the estrous cycle (2.9 +/- 0.7), compared with that from cows in the luteal phase (0.29 +/- 0.49).

Effect of zearalenone on dairy cows.

Doses of 99% pure zearalenone (0.0, 31.25, 62.5, 125.0, 250.0, or 500.0 mg) in gelatin capsules were given once a day per os to 18 nonpregnant, nonlactating, multiparous dairy cows for 2 consecutive estrous cycles. There was no effect (P less than 0.10) on serum progesterone concentrations, RBC, WBC, PCV, hemoglobin, and estrous cycle length. Differential cell counts, clinical health, and sexual behavior were not affected by the zearalenone. One cow from each of the groups given zearalenone and a control were euthanatized at the end of the study. The zearalenone had no effect on the terminal bone marrow smears and did not induce any gross lesions discernible at necropsy or any microscopic lesions in representative samples of 30 tissues/cow. Rectal palpation of the reproductive tracts once a week indicated that the corpora lutea were small in cows given zearalenone. There was a general trend to increased hemoglobin concentrations in cows given the larger doses of zearalenone. Zearalenone of and by itself does not seem to be an important factor in dairy cow health.

Effect of zearalenone on the fertility of virgin dairy heifers.

Eighteen cycling, virgin, Holstein heifers daily were given 250 mg of 99% purified zearalenone in a gelatin capsule orally, and 18 controls were given an empty gelatin capsule once a day. The study lasted through 1 non-breeding estrous cycle and the next 2 consecutive estrous cycles during which the 36 heifers were bred, using artificial insemination. Serum concentrations of progesterone and complete blood cell counts were determined throughout the study. The treated and control heifers had conception rates of 62% and 87%, respectively. There was no effect (P less than 0.05) on the serum concentration of progesterone or the complete blood cell counts. Three heifers, bred but not pregnant by the end of the study, were euthanatized and necropsied. The treated heifer did not have any zearalenone-attributable lesions, and there was no effect seen in the bone marrow smears. The remaining 33 heifers were sold as a herd, and the 31 pregnant heifers calved normally. There was no effect (P less than 0.05) on the sex ratio of the offspring, which were all clinically healthy. Zearalenone did lower the conception rate of the treated heifers (P less than 0.065).

Bioequivalency comparison between two gonadotropin-releasing hormone products.

The bioequivalency of 2 gondatropin-releasing hormone (GnRH) preparations, gonadorelin diacetate tetrahydrate and gonadorelin semicarbonate, was compared on the basis of luteinizing hormone (LH)-releasing ability of the 2 products in diestrous dairy cows. Twenty-four cycling, nonlactating Holstein cows were subjected to a double prostaglandin estrus synchronization treatment to simultaneously control stage of the estrous cycle and time factors as potential variables effecting LH responses to the treatments being studied. Circulating progesterone concentration was determined to verify stage of cycle at strategic times throughout the study. Twelve days after the second prostaglandin treatment, all cows were randomly assigned to 1 of 2 groups (n = 12). Each group of 12 cows received single doses (100 micrograms) of either GnRH preparation at the start of each test period in a 2-period crossover design. Serum samples were obtained prior to and at 12 times (10, 20, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1,440 minutes) after treatment and were assayed to determine circulating LH concentration. Significant difference between the 2 GnRH products was not found with respect to: mean concentration of LH in the blood during the 24 hours after treatment; maximal LH concentration; time from treatment to maximal LH concentration; and area under the LH concentration curve from time 0 through each of 7 times after treatment (0.5, 1, 1.5, 2, 4, 8, and 24 hours). These data confirm the bioequivalency of the 2 GnRH products.

Estradiol-17 beta cyclopentylpropionate and prostaglandin F for induction of abortion during the first trimester of pregnancy in feedlot heifers.

The ability of estradiol-17 beta cyclopentylpropionate (ECP, 20 mg) and prostaglandin F2 alpha (PGF2 alpha; 5, 10, 20, and 40 mg) to induce abortion during early gestation (days 40 to 90, as estimated by palpation per rectum) in pregnant feedlot heifers was compared. All treatments were given by IM injection. All heifers treated with 20 and 40 mg of PGF2 alpha aborted within 7 days after treatment. Six of 10 heifers aborted in the same period after ECP treatment; 1 additional heifer aborted by day 13. Abortions did not occur by day 13 in 10 placebo-treated heifers. Five and 10 mg of PGF2 alpha aborted 2 of 3 and 8 of 10 heifers, respectively, within 7 days of treatment. Quantitation of serum progesterone by specific radioimmunoassay showed that a luteolytic effect was evident in aborting heifers. Complications were not detected in any heifers after treatment or abortion. Ten of the 20 heifers that aborted in response to the 20- and 40-mg doses of PCF2 alpha developed a new corpora lutea by day 20 after treatment. However, none of the heifers that aborted after ECP treatment had a corpus luteum by day 20. It was concluded that PGF2 alpha is a more effective compound than ECP for induction of abortion during the 1st trimester of pregnancy in feedlot heifers, that a wide range of PGF2 alpha doses are capable of inducing abortion in at least some animals treated, and that heifers are likely to resume ovarian activity sooner if aborted with PGF2 alpha than with ECP.